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Abstract: 
Social movements have an important new campaigning and organizing 
competence in new information communication technologies.  These 
technologies also enable the members of social movements to readily research 
the accuracy of information:  knowledge becomes globalized and readily 
accessible.  In relation to Big Pharma, women’s social movements and social 
movements of the medicated intersect, and there is now a substantial challenge 
to Big Pharma both within developed and developing countries from the terrain of 
gender and health. This paper documents those challenges and looks towards 
their consequences in the future both in respect of Big Pharma but also in terms 
of  'academic' research. 
 
1. Introduction: Health, gender and the globalizing of knowledge 
Not one of the chief scientists or heads of research at any of the major 
pharmaceutical companies is a woman. Why that's the case is much less 
clear.  (http://www.sciencemag.org/cgi/content/summary/309/5735/724) 
 
Let’s start by visiting the International People’s Health University, an on-line 
facility operated from Nicaragua (http://www.phmovement.org/iphu/ ) and one of 
its courses (http://www.phmovement.org/iphu/en/short ).  We can see that not 
only is health knowledge being globalised but there are social movements which 
are strategizing the globalization of health knowledge. The International People’s 
Health University provides resources and training for health activists on a global 
platform and within its concerns are issues of gender and health.  It provides 
courses and knowledge on the range of global health action and in doing so 
counteracts and compensates for inequitable health practices by other 
organizations, institutions and agencies. 
 
The new information communication technologies provide a new space for 
discourse and organization by activists and new parameters for action and 
challenge.  On-line activist health personnel linked to universities provide one 
form of new social action in health, global social movements and meeting the 
challenge of AIDS/HIV provides another ( http://www.globalaidsalliance.org/ ).  
Health organizing through and around web sites generates open and searchable 
knowledge: it creates paths to knowledge for those affected by health conditions 
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and prevents such knowledge from being confined to the professional portfolios 
of experts.    
 
In this context, Big Pharma has come under challenge and within this challenge it 
is recognized that there has been a persisting gender bias of drug development 
consistent with the decade-old medicalizing of women’s bodies 
(http://www.thenhf.com/articles_169.htm ; 
http://orlando.women.it/quarta/workshops/epistemological4/pizzini.htm ).  But 
even as Big Pharma comes under challenge, and there are indeed signs of the 
success of activist challenge to the industry1, Big Pharma pushes into new 
domains and engulfs traditional areas of women’s power and health knowledge. 
The regulation of food supplements, and its removal of  many traditional food 
supplements from the marketplace altogether,  can be viewed as an undermining 
of the last bastion of  the alternative modality of the health knowledge of women -  
the unregulated traditional health space of ‘wise women’2 has finally disappeared 
(http://www.naturalnews.com/027297_corn_food_the_FDA.html  ;      
http://www.newswithviews.com/Howenstine/james24.htm ; 
http://www.newmediaexplorer.org/sepp/2005/07/12/european_court_decides_foo
d_supplements_directive_may_go_ahead.htm ).   
 
The loss of women’s power over health practice through the masculinization, 
medicalization and regulation of health over centuries is now, however, under 
challenge by women’s increasing power as consumers and by their knowledge of 
health matters as trained professional practitioners and through new information 
communication technologies.  Social movements around gender and health are 
now a feature of the modern political scene 
(http://www.womens.studies.uconn.edu/ManishaDesai1100028a.pdf ) 
and have consequences for the commercialization of medicine and treatment.  
Social justice issues have been firmly placed on the Big Pharma agenda. 
 
 
2. HIV/AIDS: From pricing out survival to ensuring gender equity in 
provision 
 
A major challenge to the pharmaceutical industry has lain in the pressure 
orchestrated by social movements and developing countries around the costs of 
HIV/AIDS medication (Little and Grieco, 2006).  Brazil, India and South Africa are 
                                                
1 Drug companies have recognized the problem. This is clear because they have promised to 
make drugs affordable and available to those living in poverty in the Global South. But so far 
they have taken few concrete steps to realize this promise—and those they have taken, like 
Gilead’s extension of its Access Program under pressure from activists, aren’t enough. 
HIV/AIDS drugs remain highly cost prohibitive. Pharmaceutical companies refuse to grant 
licenses to allow generic drugs to be produced, which would significantly reduce prices and 
increase access to lifesaving medications. http://www.globalaidsalliance.org/cd_action.cfm (decayed 
link). 
2 http://www.susunweed.com/susunweedarticles.htm#an1 
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all locations where Big Pharma has lost substantial ground around its traditional 
pricing policies which effectively priced out the survival of the affected in the 
Third World.  But these gains are not yet sufficient to ensure that the coverage 
given meets the epidemic character of the problem and there are real concerns 
that women are not well placed to obtain their share of coverage where coverage 
is made available.   
 
The involvement of the US government in the ‘war on HIV/AIDS’ has both 
produced resources for tackling the epidemic but has also created new and 
negative pressures on women’s reproductive health and well being.  The 
restrictions placed on health clinics result in those clinics which provide abortions 
not being eligible for the available US resources and the focus on funding 
abstinence campaigns draws resources away from treatment possibilities.  In its 
war on HIV/AIDS the US government invoked a close relationship with Big 
Pharma by its hiring of Randall Tobias, a major Big Pharma player, to be the US 
Global AIDS Coordinator – a post which carries Ambassadorial Status.  The 
placing of the US international HIV/AIDS program in the hands of the previous 
‘head (of) Eli Lilly and Company, one of our nation's largest and most innovative 
pharmaceutical companies’ by the Bush administration raised many questions 
about the program in a context where Big Pharma continues to receive a very 
negative press for its high pricing of critical drugs and high profitabilities in the 
health sector. 
 
The restrictions around the US HIV/AIDS program and the proximity of the 
leadership of this program to the structures and interests of Big Pharma make 
the issue of HIV/ AIDS prevention, treatment and coverage in respect of women 
particularly important.  One justification for the involvement of a Big Pharma 
player might be that such a player has the ability to identify issues concerning 
HIV/AIDS that Big Pharma is well placed to address and innovate. Research into 
differences in male and female patterns of exposure in Africa and the 
development of drug marketing programs which better reach women are two 
areas in which we might hope to see developments.  It is not clear that an over-
concentrated focus on abstinence will deliver either of these. 
 
There are many and useful discussions of the extent to which HIV/AIDS can 
classified as women’s disease within Africa  - for example, there are particular 
features of the female body which make women more vulnerable to the disease 
(http://appweb.cortland.edu/ojs/index.php/Wagadu/article/view/242/448 ). The 
involvement of Big Pharma in research which would better protect women given 
these differences would represent a useful contribution to the new declared 
social agenda of eradicating AIDS. 
 
Concerns about ensuring gender equity in the treatment of AIDS most 
particularly within US funded treatment initiatives have found public and visible 
expression: the Center For Gender and Health Equity has its 2004 submission to 
Tobias Randall, the then US Global AIDS coordinator on the web (see Gender, 
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AIDS, and ARV Therapies: Ensuring that Women Gain Equitable Access to 
Drugs within U.S. Funded Treatment Initiatives 
(http://www.genderhealth.org/pubs/TreatmentAccessFeb2004.pdf ). 
 
Box	  1:	  	  Putting	  the	  facts	  on	  the	  US	  agenda:	  an	  excerpt	  	  On	  February	  20th,	  2004,	   the	  Office	  of	   the	  Global	  AIDS	  Coordinator	  at	  the	   U.S.	   Department	   of	   State	   will	   make	   public	   the	   draft	   strategy	  guiding	  implementation	  of	  U.S.	  global	  AIDS	  policies	  authorized	  by	  the	  United	  States	  Leadership	  Against	  AIDS,	  TB,	   and	  Malaria	  Act	  of	  2003	  (.AIDS	  Act,.	   P.L.	   108-­‐25).	   The	   law	   tasks	   the	  Global	   Coordinator	  with	  developing	  programs	  to	  provide	  antiretroviral	  (ARV)	  treatment	  to	  at	  least	  2	  million	  individuals	  by	  the	  end	  of	  2006	  (with	  a	  goal	  of	  reaching	  500,000	   people	  with	   ARV	   treatment	   by	   the	   end	   of	   2004)	   (AIDS	   Act	  §402	   (a)).	   In	   support	   of	   the	   Coordinator.s	   strategy,	   Congress	   has	  provided	  $2.4	  billion	  for	  global	  AIDS	  initiatives	  in	  2004	  (Consolidated	  Appropriations	  Act,	  2004,	  P.L.	  108-­‐199)	  and	  directs	  that	  55%	  of	  these	  monies	  be	  used	  for	  the	  treatment	  of	  individuals	  with	  HIV/AIDS	  (AIDS	  Act	  §402(b)(1)).	  	  Even	  with	  increased	  commitment,	  funding,	  and	  coordination,	  U.S.	  AIDS	  treatment	  efforts	  will	  fall	  far	  short	  of	  what	  is	  needed	  to	  provide	  ARV	  treatment	  even	  to	  a	  significant	  minority	  of	  suffering	  from	  AIDS	  today.	  Currently,	  there	  are	  an	  estimated	  40	  million	  people	  living	  with	  HIV	  worldwide.	  In	  sub-­‐Saharan	  Africa,	  where	  an	  estimated	  4.1	  million	  people	  are	  infected	  with	  HIV,	  only	  50,000	  currently	  have	  access	  to	  treatment	  (Attawall	  and	  Mundy	  2003).	  The	  U.S.	  initiative	  therefore	  represents	  only	  a	  modest	  beginning	  to	  what	  must	  be	  an	  international	  commitment	  to	  prevent	  and	  treat	  HIV	  and	  AIDS.	  	  	  Given	  limited	  resources,	  choices	  will	  inevitably	  be	  made	  about	  who	  will	  be	  treated	  and	  when,	  raising	  the	  issues	  of	  equity	  in	  access	  to	  treatment	  for	  sub-­‐groups	  of	  those	  infected.	  In	  turn,	  these	  considerations	  dramatically	  underscore	  the	  need	  for	  specific	  efforts	  to	  ensure	  that	  treatment	  programs	  reach	  those	  groups.	  namely	  women	  and	  girls	  and	  other	  vulnerable	  populations,	  such	  as	  sex	  workers	  and	  men	  who	  have	  sex	  with	  men,	  which,	  due	  to	  social,	  economic,	  and	  cultural	  discrimination	  and	  lack	  of	  access	  to	  health	  care,	  already	  face	  a	  disproportionately	  higher	  risk	  of	  infection.	  Today,	  for	  example,	  women	  represent	  more	  than	  half	  of	  those	  infected	  with	  HIV	  worldwide,	  and	  more	  than	  60	  percent	  of	  those	  infected	  in	  sub-­‐Saharan	  Africa	  (UNAIDS	  2003).	  In	  many	  countries,	  the	  rate	  of	  new	  infections	  is	  highest	  among	  married	  women	  and	  adolescent	  girls.	  	  The	  failure	  to	  understand	  and	  address	  the	  barriers	  to	  treatment	  access	  faced	  by	  women	  and	  girls	  will	  undermine	  investments	  made	  by	  the	  United	  States	  to	  seek	  long-­‐term	  and	  sustainable	  solutions	  to	  the	  global	  HIV/AIDS	  epidemic.	  	  	  To	  ensure	  that	  U.S.	  global	  AIDS	  strategies	  promote	  justice	  and	  equity	  and	  reflect	  international	  consensus	  on	  the	  ethical	  principles	  guiding	  access	  to	  health	  care,	  the	  United	  States	  must	  take	  proactive	  steps	  to	  address	  the	  barriers	  to	  access	  faced	  by	  women.	  There	  is	  no	  consistent	  
 5 
formula	  for	  ensuring	  equity	  in	  access	  to	  treatment	  given	  scarce	  resources.	  At	  the	  same	  time,	  a	  set	  of	  standard	  considerations,	  guidelines	  or	  questions	  can	  and	  must	  be	  formulated	  and	  applied	  within	  each	  setting	  to	  ensure	  that	  concerns	  for	  gender	  equity	  and	  social	  justice	  are	  incorporated	  into	  treatment	  access	  schemes.	  Such	  guidelines	  can	  be	  used	  to	  ensure	  consistent	  application	  of	  ethical	  principles	  to	  treatment	  access,	  while	  reflecting	  specific	  circumstances,	  and	  should	  be	  carefully	  reviewed	  on	  a	  regular	  basis	  in	  response	  to	  changes	  in	  the	  dynamics	  of	  the	  epidemic	  or	  as	  treatment	  access	  expands.	  
http://www.genderhealth.org/pubs/TreatmentAccessFeb2004.pdf 
 
This submission makes the important call for female controlled prevention 
technology to be developed in the campaign to eradicate AIDS. From the 
statistics given in this submission, we can easily view the unmet need in terms of 
coverage and the extent to which gender plays a part in determining membership 
of the unmet need category.  The call for research and development around 
microbicides as a technology which would particularly benefit women in the 
context of HIV/AIDS made in this submission is also made most powerfully by the 
International Community of Women Living with AIDS (http://www.icw.org/tiki-
read_article.php?articleId=25 ; http://www.global-campaign.org/  ). 
 
The social movement pressure to lower the prices of critical drugs and to extend 
coverage of HIV/AIDS treatment  
(http://www.afrol.com/html/Categories/Health/backgr_medicine_poverty.htm )  by 
the direct lobbying of Big Pharma has its counterpart in the lobbying of  
governments and international institutions.  The pressure to discard unjust 
international arrangements in the context of regional health crises grows; the 
protection of patents at the cost of public health, including women’s health, 
becomes increasingly unacceptable (http://www.avert.org/generic.htm ).  The 
International Community of Women Living with AIDS (http://www.icw.org/tiki-
read_article.php?articleId=198) is presently active in attempting to end TRIPS-
plus provisions which threaten access to medicines: 
 
Box  2: US Patent Protection: the implications for public health 
International NGO Solidarity Statement: US-Thai Free Trade Negotiations 
Threaten Access to Medicines; Activists Demand Suspension of Negotiations 
and End to TRIPS-plus IP Provisions  
 
Jan. 9, 2006. Thai AIDS activists and their international allies are seeking 
suspension of scheduled trade talks that threaten to undermine Thailand's 
lawful ability to produce, import/export, and market low-cost generic 
versions of life-saving medicines. Today, in Chiang Mai, the United States 
and Thailand are scheduled to start the Sixth Round of negotiations on a 
proposed Free Trade Agreement and for the first time are holding 
discussions on a U.S. proposal to dramatically increase intellectual property 
protections for pharmaceutical products. Simultaneously, ten thousand Thai 
activists, half of them living with HIV, are protesting the scheduled talks and 
trying to shut them down, promising to sleep overnight outside the meeting 
venue for three nights and to block entry to the negotiations.  
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The U.S. government has consistently refused to release the draft text of its 
FTA proposals and simultaneously extracts promises of secrecy from its 
negotiating partners. This shroud of secrecy limits democratic review and 
civil society participation in the negotiation process. In particular, it denies 
voice to the tens of thousands of Thais living with HIV/AIDS who need 
increased access to affordable second-generation antiretroviral and 
opportunistic infection medicines that are currently patent-protected and 
cost prohibitive.  
 
Instead of allowing Thailand to use all existing flexibilities for accessing 
cheaper medicines under international law as confirmed by the 2001 WTO 
Doha Declaration on the TRIPS Agreement and Public Health and by the UN 
Commission on Human Rights, the U.S., based on past practice, will be 
seeking to heighten patent and data protection in the following ways:  
- Extending patent terms beyond 20 years to compensate for administrative  
delays and easing standards of patentability on new formulations and uses,  
thereby extending the period of monopoly pricing;  
- Restricting rights to parallel import cheaper medicines by codifying  
patent-holders' rights to contractually limit export/import of previously sold 
products;  
- Potentially restricting the grounds for issuing compulsory licenses;  
- Linking marketing approval to the absence of claimed patent rights and 
imposing 5-10 year data-exclusivity provisions (preventing reliance on 
proprietors' clinical trial data to grant marketing approval for generic 
products), thereby potentially restricting compulsory licensing rights;  
- Imposing criminal penalties on companies that intentionally or  
inadvertently violate patents.  
 
The U.S. attempts to down-play the significance of these hard-text treaty terms 
with an ambiguous and under-inclusive "side-letter" reaffirming trade partners' 
rights to prioritize access to medicines. Such side-letters make no binding 
commitments, and the USTR has expressly declined to confirm the obligatory 
effect of the letters when asked to do so in response to Congressional inquiries.  
 
Consistent with human rights norms requiring access to essential medicines 
and in response to Thai activist demands, Thailand has initiated a program 
of universal access to government-subsidized antiretroviral drugs that now 
reaches 70,000 of 170,000 Thai people living with HIV/AIDS. However, the 
future costs of expanded treatment with newer patented medicines will be 
prohibitive if the U.S. succeeds in its objectives to ratchet-up intellectual 
property protections.  
 
Therefore, we join our Thai colleagues at Chiang Mai and throughout 
Thailand demanding that the U.S. suspend negotiations on intellectual 
property rights and that it drop all intellectual property provisions affecting 
access to pharmaceutical products, specifically all TRIPS-plus terms, in the 
Thai FTA and in other FTAs as well. In addition, we demand that the U.S. 
publish its proposed text for the entire FTA and that the Thai people have 
had a chance to hold public consultations on the proposed agreement.  
 
Signed,  
-50 Years is Enough Network  
-ACT UP East Bay, USAACT UP New York, USA  
-ACT UP Philadelphia, USA  
-ActionAid International, USA  
-AIDS Foundation of Chicago, USA  
-American Jewish World Service, USA  
-Australian Women's Health Movement, Australia  
 7 
-Boston Women's Health Book Collective, USA  
-Canadian HIV/AIDS Legal Network, Canada  
-Center for Policy Analysis on Trade and Health, USA  
-Community HIV/AIDS Mobilization Project (CHAMP), USA  
-Consumer Project on Technology, USA  
-Egyptian Initiative for Personal Rights, Egypt  
-Essential Action, USA  
-European AIDS Treatment Action Group (EATG)  
-Gays and Lesbians of Zimbabwe (GALZ), Zimbabwe  
-Global AIDS Alliance, USA  
-Globalization and Health Project, Centre for Governance of Knowledge and 
Development  
-Harm Reduction Coalition, USA  
-Health Action International Asian Pacific  
-Health Connections International, The Netherlands  
-Health GAP (Global Access Project), USA  
-Health Rights Action Group, UgandaHIV/AIDS Task Force, Africa Japan  
Forum, Japan  
-Human Rights Watch, USA  
-International Community of Women Living with HIV/AIDS (ICW)  
-Medical Action  
-Cooperation with Cuba (MEDICC), USA  
-Mobilization for Global Justice, USANational Association of People with AIDS 
(NAPWA)  
-USANGO Coalition of People Living with HIV/AIDS, Moldova  
-Our Bodies, Ourselves, USA  
-Oxfam America, USA  
-People's Health Movement, USA  
-Public Citizen, USA  
-Public Health Association of Australia, Australia  
-San Francisco Tobacco Free Coalition, USA  
-Saniplan.org, USA  
-Soropositividade, Comunicação e Gênero (GESTOS), Brazil  
-Southern Initiatives, India  
-Student Global AIDS Campaign, USA  
-Thai AIDS Treatment Action Group, Thailand  
-The Global Network of People with AIDS (GNP+), The Netherlands  
-Third World Network, Malaysia  
-Uganda Treatment Access Movement, Uganda  
-Universities Allied for Essential Medicines, USA  
 http://www.icw.org/tiki-read_article.php?articleId=198 
 
The United States protection of its pharmaceutical industry whilst simultaneously 
mounting its campaign for the reduction of HIV/AIDS can certainly be viewed as 
contradictory or at the very least paradoxical.   This protection of US trade 
interests would lead to a reduction in HIV/AIDS coverage: and clearly this conflict 
replicated across the affected regions of the world represents a major obstacle to 
any effective campaign for global AIDS eradication.  
 
Gender and health issues around HIV/AIDS are many and social movement 
activity around each of these issues is substantial.  In this short section, we have 
indicated that there are good reasons for Big Pharma to pay attention to these 
issues of gender and health in the context of this global epidemic: the 
transparency of profit in situations of endangered public health, the visibility of 
industry and government alliances which threaten declared ethical and moral 
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global health agendas and the mounting global public discontent with these 
arrangements are all made more tangible by the new information communication 
technologies. The sustainability and continuous accessibility of this expression of 
discontent too is enabled by these technologies.  The public representation of the 
impact of the action of Big Pharma on the women of the world is no longer 
confined to the well funded public relations of the industry itself but has other 
alternative and more negative manifestations with which the industry’s own 
marketing must now interact. 
 
 
3  A directable market?:  The medicalization of  ‘women’s problems’ 
 
In contrast to the HIV/AIDS situation where women need the services of Big 
Pharma at affordable prices, there are also many situations where women 
receive the attentions of Big Pharma but where it can be argued that these 
attentions are misplaced.   There is a growing literature which speaks to the 
medicalization of ‘women’s problems’ by Big Pharma through its highly 
aggressive marketing strategies.  The targeting of doctors through ‘perks’ and 
aggressive public relations so as to result in the prescribing of unnecessary 
medications for women has received  substantial attention in the literature.  
Hartley’s (2003) work on the medicalization of women’s sexual problems by Big 
Pharma  provides the reader with a good starting point (see "Big Pharma" in our 
bedrooms: an analysis of the medicalization of women's sexual problems (H. 
Hartley) 
http://www.elsevier.com/wps/find/bookdescription.cws_home/680869/description
#description). 
 
Recently the work of Moynihan and Cassel (2005) has drawn attention to the Big 
Pharma syndrome of ‘selling sickness’, however, in their analysis they fail to 
engage with the gender dynamics involved.  Abby Lippman provides the 
following review of their work: 
 
Lessons learned from the women's health movement (then and now) offer models for 
how to deal with today's sickness- and drug-sellers. But Moynihan and Cassels don't 
sufficiently acknowledge the persisting gender bias of drug development and the 
decades-old medicalizing of women's bodies, even though six of the 10 conditions 
analyzed in Selling Sickness are conditions experienced by -- and treated more in -- 
women than men. 
This is not coincidence: Women are sold sickness and also use drugs more often than 
men. Moynihan and Cassels are at their best detailing how selling sickness is happening. 
But their analytic lens isn't sufficiently wide, so they don't connect their themes to 
ongoing activities with huge potential to create diseases-in-waiting for drugs of the 
future (e.g., brain imaging to "see" why we [mis]behave as we do, or gene mapping to 
seek DNA patterns that make us "susceptible" to just about anything). Moreover, while 
Selling Sickness has abundant references to the actions of the U.S. Food and Drug 
Administration, the Canadian content sometimes feels more like an "add on" than part 
of an integrated whole. 
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A range of well-intentioned proposals is now under consideration in Canada and 
elsewhere to rein in some of the worst practices described in Selling Sickness. 
These include mandatory public registration of all drug trials, mandatory 
reporting of adverse drug effects and updated requirements for declarations about 
sources of funding by researchers, "expert" advisers and patient groups. If these 
come into practice, perhaps they'll alleviate some problems. But by themselves, 
they can't prevent the growing health burden caused by the continued massive 
selling of sickness -- and of harmful drugs.  @ 
http://www.naturalhealthcoalition.ca/big_pharma.htm (decayed link) 
The ‘persistent gender bias of drug development’ identified here by Lippman is 
well exampled by the history of Hormone Replacement Therapy to ‘counteract’ 
the menopause.  A recent review provides an indication of the scale of the 
medicalization of a normal female condition: 
 
A hot flush for Big Pharma  
How HRT studies have got drug firms rallying the troops  
So the headlines have dealt another blow to the image of hormone replacement 
therapy (HRT). Will the drug companies be able to revive the fortunes of one of 
their most lucrative products? Will the big guns of the pharmaceutical industry be 
blazing, eager to counteract the latest volley of bad publicity? Or will the industry 
construct its defences more subtly? …….But what exactly can the PR machine do 
in the face of evidence that now says long term HRT use increases women's risk 
of blood clots, strokes, heart attacks, breast cancer, and dementia, and has no 
quality of life benefits? Probably what it has always been doing—promoting the 
idea of HRT both as a cure for a medicalised menopause and an elixir even in the 
absence of scientific data. ……….More than 100 million women worldwide—1.5 
million in Britain—took HRT in 2001 and global sales amounted to $3.8bn 
(£2.4bn; €3.4bn). But after the first wave of publications from the WHI study, 
Wyeth, which accounts for more than 70% of the global market, saw its share 
price plummet. The stock, which traded as high as $58.48 (£36.48; €51.66) in May 
2002, fell by almost half to a low of $28.25 in July. 
(http://bmj.bmjjournals.com/cgi/content/full/327/7411/400 ) 
The rapid impact of negative research findings on pharmaceutical fortunes is 
easily seen from this case.  Equally, the inadequacy of previous research into 
side effects is also revealed.  Similarly, the history of Depo Provera, an injected 
contraceptive, provides a case history of inadequate investigation into and 
publication of the drugs side effects by Big Pharma The failure of Big Pharma to 
provide adequate information on the side effect of drugs has been met by the 
development of consumer or user websites where the difficulties are reported 
and recorded by those who have experienced them.  These sites provide a 
counterweight to the glossy public relations materials of the industry and a record 
where the industry has failed to follow up on user experience.  Women’s 
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experiences and views of Depo Provera can be found at   
http://womenshealth.about.com/cs/birthcontrol/a/depoproverabc.htm : this 
includes the opportunity to join on-line petitions.  Scattered users can coordinate 
through the new technology and exchange experiences: the side effects of Depo 
Provera become widely discussed through this forum. 
The dangers of Depo Provera have been recognized by US authorities but this 
does not prevent the contraceptive being aggressively marketed in the Third 
World: 
Pushing Depo-Provera  
Halcion is not the first Upjohn drug which has endangered women and whose 
clinical tests have generated charges of misconduct. Upjohn's contraceptive Depo-
Provera is marketed throughout the world, even though the FDA has refused to 
approve it for use as a contraceptive in the United States.  
Injected into the arm or buttock in a 150 milliliter dose,one shot of Depo-Provera 
prevents conception for at least three months. Upjohn aggressively markets the 
hormonal contraceptive outside the United States, particularly to women in the 
Third World. According to Upjohn, Depo-Provera is currently registered or 
approved in more than 90 countries.  
Critics of Depo-Provera believe Upjohn is exposing Third World women to 
serious dangers [see "The Case Against Depo-Provera," Multinational Monitor, 
February/ March 1985]. Animal tests of the drug required for the FDA approval 
process found breast tumors in dogs and endometrial cancer in monkeys. 
According to the National Women's Health Network, animal and clinical studies 
further link use of the drug with infertility, diabetes and hypoglycemia, anemia, 
increased risk of blood clots and excessive bleeding leading to a need for 
hysterectomies.  
(http://multinationalmonitor.org/hyper/issues/1991/11/knaus.html ) 
The aggressive marketing of drugs targeted on vulnerable social groups such as 
illiterate women is a feature of Big Pharma’s agenda long ripe for reformation.  In 
closing this section, let us take a glimpse at the latest item on the Big Pharma 
gender agenda for medicalization – female sexual dysfunction. Moynihan, one of 
the author’s of Selling Sickness draws our attention to the problems experienced 
in the attempts to launch this blockbuster medicalization of women’s biology: 
Robert Wilson's bestselling book Feminine Forever helped persuade the modern 
world that the menopause was a "disease" of hormone deficiency, to be cured with 
hormone replacement.1 The book's 1966 front cover promised, "Every woman no 
matter what her age, can safely live a fully-sexed life for her entire life," and the 
hormones sold by Wilson's sponsor duly became best sellers. Forty years later, 
long term hormone replacement has been exposed as doing more harm than good, 
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drug sales have collapsed, and Wilson's thesis is rightly ridiculed as corporate 
sponsored disease mongering.2 3  
In the shadows of this overmedicalisation, the pharmaceutical industry is meeting 
unexpected resistance to its attempts to sell women the next big profitable 
"disease," female sexual dysfunction. This condition is claimed by enthusiastic 
proponents to affect 43% of American women,4 yet widespread and growing 
scientific disagreement exists over both its definition and prevalence. In addition, 
the meaningful benefits of experimental drugs for women's sexual difficulties are 
questionable, and the financial conflicts of interest of experts who endorse the 
notion of a highly prevalent medical condition are extensive. These controversies 
have been brought into focus by the rejection of Proctor and Gamble's 
experimental testosterone patch by advisers to the US Food and Drug 
Administration in December 2004.5  
(http://bmj.bmjjournals.com/cgi/content/full/330/7484/192 ) 
Once again the technology enables women to organize and coordinate their own 
experiences into a body of health knowledge which challenges the public 
relations of the industry.  Individual negative experiences can be aggregated and 
are.  Informed  materials can be accessed readily through the technology and 
governments, international agencies and companies can be targeted, petitioned 
and lobbied through the use of the technology with minimum effort by women’s 
social movements. 
 
4.  Engulfing the alternative: The battle of the supplements 
 
In the introduction to this presentation we drew attention to the history of wise 
women and their use of local plants and natural substances in the practice of 
medicine.  Folk practices of medicine making have been identified by 
pharmaceutical companies and with relatively little transformation harnessed as 
product under patent to substantial profit without regard or payment to the 
owners of indigenous knowledge 
(http://www.bayeraspirin.com/questions/hundred_aspirin.htm ): the San people of 
South Africa have broken this pattern and receive  remuneration for the 
development of a diet drug from a plant that they have used to suppress hunger 
while on trek for generations:  
 
South Africa's indigenous San peoples have signed a deal ensuring 
they will profit from a diet drug being developed from a plant they 
have used for generations.  
Under the terms of the agreement, the San people will receive regular fees as 
the drug - developed from a plant used to suppress the appetite - passes 
various stages on the way to market.  
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They will also receive a proportion of the royalties if and when it becomes 
commercially available, which could be in as little as five years.  
The San people hailed the agreement as a "joyous moment".  
"In the past, it used to be the norm to exploit their knowledge and culture but 
today is an example of how things have changed," said Kxao Moses, chairman 
of the Working Group of Indigenous Minorities in Southern Africa. 
(http://news.bbc.co.uk/1/hi/world/africa/2883087.stm ) 
This represents the first deal of its kind and its occurrence is to be welcomed, 
though no doubt the anti-obesity drug will be marketed heavily and aggressively 
for women, however, this occurs at the same time as food supplements have 
come under international regulation.  Such supplements had been part of the 
ground of alternative medicine and alternative health practices – an extension in 
some ways of wise women practice – but the regulation of these supplements 
advantages Big Pharma as the producer of such supplements with increasing 
prices of some and the eradication of others. 
 
Box 4:  the battle of the supplements 
CODEX ALIMENTARIS 
ENDS U.S. SUPPLEMENTS 
IN JUNE 2005  
  
  
  
By Dr. James Howenstine, MD. 
March 6, 2005 
NewsWithViews.com 
Working stealthily BIG PHARMA has rapidly pushed their 
legislative program (Codex Alimentaris) in Europe that will 
eliminate the free choice Americans now have to purchase 
vitamins, herbs, minerals, homeopathic remedies, aminoacids 
and nutritional supplements. This elimination of all competition 
for the pharmaceutical industry will produce an enormous 
increase in the already exorbitant profits earned by the 
pharmaceutical firms. Of even greater significance the lack of 
free choice to stay well by taking effective nutritional substances 
will promptly be followed by a sharp increase in illnesses that 
will only be treated in the future with pharmaceutical drugs.  
The new Codex Alimentaris adopted in a secret meeting in 
Europe in November 2004 is scheduled to take effect in June 
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2005. Because the United States belongs to the World Trade 
Organization WTO any changes approved in Europe 
automatically become law in the United States superceding our 
own laws (we are no longer a sovereign nation). Failure to comply 
with these changes institutes lawsuits which can not be won as 
they are settled in international courts which care nothing about 
U.S. laws. Incidentally, Europe has been very leery of genetically 
modified foods because of serious concerns about their safety. By 
this same WTO mechanism Europe will be forced to accept 
importation of U.S. GMO foods even if they know they are bad for 
health.  
The features of Codex Alimentaris are:  
• No supplements can be sold for preventative or 
therapeutic use.  
• Any potency higher than RDA levels (pathetically low) is a 
drug that requires a prescription and must be produced 
by drug companies.  
• Codex regulations are binding internationally  
• New supplements are banned unless given Codex testing 
and approval (certain to expensive and lacking in 
scientific merit). Norway and Germany are already 
operating under the new Codex regulations. The price of 
zinc tablets has gone from $4 to $52. Echinacea has risen 
from $14 to $153.  
• Codex regulations are not based on science or research 
findings. These regulations were developed by 11 
appointed persons. Guess who appointed them? 
http://www.newswithviews.com/Howenstine/james24.htm 
 
Supplement use is consistently higher in women than in men and it is this group 
that the regulation of supplements will affect.  In the battle of the supplements, 
Big Pharma is well placed to encompass and engulf its last existing competitor.  
“Folk” suppliers of supplements as matters stand appear set to disappear. 
 
5.  Conclusion: Purchasing authority 
 
In the course of this argument, we have seen that the combination of gender and 
health social movements have presented a challenge to Big Pharma both in 
political terms and as departing consumers.  We have seen that there has 
historically been a failure to adequately inform women of the side effects of the 
drugs with which they are medicated, that there has been a failure to research 
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thoroughly and follow up on side effects of widely prescribed medications and 
that there has been a failure to develop appropriate medication for public health 
where profitabilities were judged to be low. 
 
We are now in a time when Big Pharma has come under visible pressure for its 
‘ethical’ behavior, whilst at the same time Big Pharma’s controls over many areas 
of its activity, perversely, have strengthened.  These strengthening controls are 
coming under increasingly forceful and forcible pressure and the contradictory 
position of the US government in terms of strengthening the power of US drug 
patents whilst eradicating AIDS is increasingly transparent.  
 
The technology, we have argued, makes a radical difference to the ability of 
social movements to both track and display the activities of Big Pharma and 
women’s social movements have made maximum use of this technology as have 
gender and health organizations and activists.  But the technology is also 
revealing the business of the link between the academy and the industry.  
Historically, the academy or university was seen as the location of independent 
and accurate research but recent events around Big Pharma and a British 
University portray a tale of purchased authority and legitimacy by the industry. 
 
Procter and Gamble had placed research with the university and received data 
back from the university but proceeded to publish findings from this research 
without involving the primary researcher in the processing and analyzing of the 
data whilst at the same time placing his name amongst others on the findings 
which were very favorable to their product – a product to be used by women.  
The researcher asked for access to the data set which was being published 
under his name amongst others and was told that the industry standard was that 
he be not given such access.  He protested to the company and to his university 
and eventually took his story to the press as a whistleblower.  His University 
placed him under disciplinary procedures and then attempted to terminate his 
employment with a package: the pharmaceutical company was a major source of 
research funding. 
 
The researcher has continued to draw attention to the issue and has gained 
support for his campaign within the United States: 
 
Box 5:  Purchasing authority – Big Pharma standards 
Blumsohn works for Sheffield University in England, where he is a senior 
medical faculty member specializing in bone health. In 2002, Sheffield entered 
into a contract with P&G to collect Actonel data – the purpose of which was to 
determine how the drug prevented bone fractures, and how this related to 
change in bone resorption (the rate at which bone is removed) and bone 
mineral density. Consistent with research protocols in collecting data, 
Blumsohn was blind to which research subjects received Actonel and who got 
placebos. To later analyze the data, he needed its key, P&G’s “randomization 
codes.” Despite his repeated requests over 18 months, P&G denied him 
access to the data, even as it published ghost-written abstracts in his name 
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falsely implying the therapeutic equivalence of Actonel to Merck’s Fosamax, 
the industry leader.  
Researchers are supposed to be granted access to full data sets to reach 
informed conclusions. In 2001, an international coalition of the world’s leading 
medical journal editors called for all journal article authors to pledge that they 
had “full access” to drug study data. This was recommended in order to avoid 
data manipulation by corporate sponsors of product information. That editorial 
appears in the September 18, 2001 edition of the Annals of Internal Medicine.  
In 2004, P&G allowed Blumsohn to review, at one of its British facilities, what 
the company purported to be the actual data set. In reviewing the data, 
Blumsohn realized that numerous graphs (illustrating Actonel’s effectiveness in 
preventing bone fractures) omitted 40 percent of a data set, apparently 
manipulating results to suit P&G’s marketing objectives. P&G officials told 
Blumsohn that if these additional data were included in the results, the study 
would have favored a competitor’s drug – Merck’s Fosamax.  
Since that time, Blumsohn has kept raising his concerns regarding P&G with 
Sheffield University, which subsequently offered him a large sum of money to 
leave his post. He refused because the settlement agreement required his 
silence; he was suspended by the university for speaking out about the issue 
to the BBC. GAP accepted him as a client earlier this year.  
“This is all about the way in which science is conducted,” states Blumsohn. 
“Pharmaceutical companies have succeeded in overturning the usual 
safeguards and procedures of science for corporate purposes. These drug 
companies use universities to give research a veneer of respectability and 
credibility.”  
http://www.commondreams.org/news2006/0222-05.htm 
 
 
 
 
The actions of this researcher laid bare and revealed suspect practices within the 
industry. After some considerable time and only after the press campaign had 
begun did the pharmaceutical company adjust its behavior: 
 
A pharmaceutical giant has promised to give a full guarantee of 
independence to academic researchers whose work it funds in a move 
that follows widespread concern over the company's handling of a major 
UK drugs study. 
(http://observer.guardian.co.uk/uk_news/story/0,,1718179,00.html ) 
 
 
The globalizing of awareness around suspect practices by Big Pharma creates 
the need for reform and for a new public relations which better meets and 
respects the real needs of the gender and health agenda.  The globalizing 
awareness also has consequences for Big Pharma’s partners including the 
 16 
Universities.  Big Pharma surely represents an important ground of challenge for 
the new Obama administration with its commitment to an improved health 
agenda, an agenda which must surely engage with the experience and evidence 
so abundantly provided by the gender and health social movements not least in 
respect of HIV/AIDS. 
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